City Therapeutics, Inc. CTY
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -13.75%
- 1 year
- -13.75%
5D +2.20 (+12.29%)
- Market cap
- 1.03B
- Revenue (ttm)
- 14.34M
- EPS (ttm)
- -2.53
- Shares out
- 53.39M
- Forward P/E
- -6.36
- YTD return
- -13.75%
- 1-year return
- -13.75%
- 50-day average
- 19.45
- Volume
- 250.12K
- Avg volume
- 332.02K
- Open
- 18.35
- Previous close
- 18.35
- Day's range
- 16.96 – 20.62
- 52-week range
- 15.81 – 23.88
- Analysts
- Strong Buy
- Price target
- 37.33 (+93.2%)
Key statistics
- 200-day average
- 19.45
- Enterprise value
- 240.52M
- Price / sales
- 71.73
- Revenue growth
- 14.00%
- Total cash
- 169.60M
- Total debt
- 57.04M
Fundamental scorecard
4 of 25 checks passed on CTY’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Jefferies | init | — | Buy |
| Nov 10, 2026 | Oppenheimer | init | — | Outperform |
| Nov 10, 2026 | Goldman Sachs | init | — | Early-Stage Biotech |
| Nov 10, 2026 | Stifel | init | — | Buy |
About City Therapeutics, Inc.
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- citytx.com
News
Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46
City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1
Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating
Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34
Your note
Sign in to keep a note on CTY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 18, 2026 | 0 |
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | Oct 18, 2026 | 2,107,710 |
